[ORGANIZATION]
SELLAS Life Sciences Group, Inc.
Featured in 2 tracked stories · first seen
Situations
Sellas Life Sciences cancer vaccine clinical trials
2 clusters · 4 sources · last updated
Latest: Galinpepimut-S vaccine reduces leukemia death risk by 41%
Sellas Life Sciences reported successful results from its Phase 3 REGAL study for the peptide vaccine Galinpepimut-S (GPS), intended to treat acute myeloid leukemia (AML). The study met its primary endpoint of statistica
Also covered in
-
Institutional investors adjust stakes in Eli Lilly and SELLAS Life Sciences
[BUSINESS] · 2 sources ·